VERAXA Biotech AG (NASDAQ: VRXA) has announced that its VXA-222 bispecific antibody-drug conjugate (bsADC) program has advanced beyond the discovery phase, marking a significant milestone in the company's oncology pipeline. The program, which leverages the company's proprietary antibody engineering, linker, and conjugation technologies, is now entering the next stage of development with preclinical validation.
The advancement follows the completion of the discovery portion of VERAXA's collaboration with OmniAb Inc., which began in May 2025 (https://nnw.fm/nIprz). OmniAb delivered a portfolio of therapeutic antibody binders, and VERAXA will now engineer the final bispecific ADC candidate. Although VXA-222 is not based on VERAXA's BiTAC platform, it underscores the company's ability to integrate diverse technologies to advance its pipeline.
In parallel, VERAXA has expanded its intellectual property portfolio with its first BiTAC-related patent filings, along with additional patents covering conjugation chemistry, payloads, and antibody technologies. The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, with newly filed applications expected to extend protection into at least 2047.
This dual progress—advancing a key program and broadening IP—positions VERAXA to strengthen its competitive edge in the oncology space. The company continues to build a diversified pipeline that includes bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats targeting difficult-to-treat cancers.
The implications of these developments are significant for VERAXA's stakeholders. The VXA-222 program's progression could lead to a viable therapeutic candidate, potentially addressing unmet medical needs. The expanded patent portfolio not only protects the company's innovations but also enhances its valuation and attractiveness to potential partners or investors.
Moreover, the collaboration with OmniAb highlights VERAXA's strategy of leveraging external expertise to accelerate development. By combining OmniAb's binder discovery with its own engineering capabilities, VERAXA aims to create next-generation ADCs with improved efficacy and safety profiles.
As VERAXA moves forward, the focus will be on preclinical validation and advancing VXA-222 toward clinical trials. The company's commitment to innovation and IP protection is evident in its expanding portfolio, which is expected to support long-term growth and differentiation in the competitive oncology market.
For more information on VERAXA and its latest updates, visit the company's newsroom at https://nnw.fm/VRXA.
